Evolus, Inc. $EOLS Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 594.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 259,487 shares of the company’s stock after acquiring an additional 222,126 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.40% of Evolus worth $2,390,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock worth $38,906,000 after acquiring an additional 62,664 shares in the last quarter. Millennium Management LLC raised its position in Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after acquiring an additional 23,605 shares in the last quarter. Nuveen LLC purchased a new position in Evolus in the first quarter worth $12,330,000. Lord Abbett & CO. LLC raised its position in Evolus by 7.2% in the first quarter. Lord Abbett & CO. LLC now owns 533,599 shares of the company’s stock worth $6,419,000 after acquiring an additional 35,750 shares in the last quarter. Finally, Zimmer Partners LP raised its position in Evolus by 21.2% in the first quarter. Zimmer Partners LP now owns 505,000 shares of the company’s stock worth $6,075,000 after acquiring an additional 88,500 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on EOLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evolus in a research report on Tuesday, October 14th. HC Wainwright cut their price objective on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. BTIG Research reiterated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a research report on Monday, September 8th. Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Finally, Needham & Company LLC reiterated a “hold” rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, August 6th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evolus presently has a consensus rating of “Hold” and a consensus price target of $21.25.

Evolus Stock Down 2.0%

Shares of NASDAQ:EOLS opened at $6.72 on Friday. The stock’s fifty day simple moving average is $6.78 and its 200-day simple moving average is $8.53. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.44. The company has a market capitalization of $434.68 million, a P/E ratio of -6.86 and a beta of 1.04.

Insider Activity

In other Evolus news, Director Brady Stewart bought 30,000 shares of Evolus stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the transaction, the director owned 88,629 shares of the company’s stock, valued at $604,449.78. This represents a 51.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares in the company, valued at $675,516.99. This trade represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.90% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.